Aetna Clinical Policy Bulletin: Total Knee Arthroplasty (TKA)
Policy Number: CPB 0650 | Effective Date: January 1, 2024

POLICY SUMMARY
Aetna considers total knee arthroplasty medically necessary for patients with
end-stage knee osteoarthritis or rheumatoid arthritis who have failed conservative
management and demonstrate significant functional impairment.

CLINICAL CRITERIA â€” ALL of the following must be met:

1. DIAGNOSIS CONFIRMATION
   Primary osteoarthritis (ICD-10: M17.x) or rheumatoid arthritis (M06.x)
   confirmed by weight-bearing radiographs of the affected knee.

2. RADIOGRAPHIC SEVERITY
   Kellgren-Lawrence grade 3 or 4 joint space narrowing on standing AP views.
   Grade 3: definite osteophytes, moderate joint space narrowing.
   Grade 4: large osteophytes, severe narrowing, subchondral sclerosis.

3. CONSERVATIVE TREATMENT FAILURE (>= 6 months total)
   a. Physical therapy: minimum 12 visits with documented functional outcomes
   b. NSAIDs or analgesics: adequate trial duration
   c. At least 1 intra-articular corticosteroid or hyaluronic acid injection

4. FUNCTIONAL IMPAIRMENT
   Significant functional impairment documented by validated instrument:
   - WOMAC total score indicating moderate-to-severe disability, OR
   - KOOS (Knee Injury and Osteoarthritis Outcome Score) demonstrating
     significant impact on daily activities, sport, and quality of life

5. AGE CONSIDERATION
   Age >= 50 years. Patients < 50 may be considered with documented severe
   joint destruction and exhaustion of all joint-preserving alternatives.

6. BMI REQUIREMENT
   BMI < 40. If BMI >= 40, documented participation in weight optimization
   program required.

REQUIRED DOCUMENTATION:
- Weight-bearing knee radiographs (AP, lateral, sunrise views)
- Physical therapy records with functional scores
- Injection procedure notes
- WOMAC or KOOS assessment scores
- Pre-operative medical clearance

APPLICABLE CPT CODES:
27447, 27446, 27486, 27487

APPEAL DEADLINE: 45 calendar days from denial notification

GUIDELINE SOURCE: Aetna Clinical Policy Bulletin 0650
